15 Proven AI Startups to Invest In:
Techniques Most Experts Won’t Tell You
A brutally honest, data-backed guide to the most investable AI companies of 2026 — what actually makes them defensible, how retail and accredited investors can realistically access them, and what the breathless coverage skips.
This article is for informational purposes only. It does not constitute investment advice. AI private equity is a high-risk, often illiquid asset class. Consult a registered financial adviser before allocating capital. All figures cited are sourced from public disclosures, Sacra, Crunchbase, PitchBook, and named media reports as of May 2026.
Let me be honest about something that most AI investment guides won’t say upfront: the headline numbers are frequently misleading. When you read that xAI raised $42 billion or that Cursor crossed $2 billion ARR, those figures are real — but the implied investment opportunity is almost always inaccessible to 87% of investors. The rounds were already closed. The secondary market has months-long waitlists. And the funds you can actually buy into charge 2-and-20 on top of a premium valuation.
So this guide does something different. It pairs honest startup analysis with an honest look at how people can actually get exposure — secondary markets, publicly traded proxies, AI-focused funds available to retail investors — without pretending that everyone is a Sequoia LP.
That said: the opportunity itself is real. AI startups attracted $192.7 billion in global venture capital in 2025 — over 48% of all VC deployed worldwide, according to data tracked by Second Talent. That’s not hype; it’s structural. The companies below are winning actual enterprise contracts, not just demo competitions.
Table of Contents
Why This Moment Is Different (And Why Most Coverage Gets It Wrong)
Here’s what most financial media doesn’t tell you: the AI investment story isn’t a single cohesive bet. It’s at least four different bets, each with entirely different risk profiles. Foundation model companies like OpenAI and Anthropic are betting that winner-take-most dynamics will produce trillion-dollar outcomes — and they’re burning cash at rates that require those outcomes to actually materialise. Vertical AI companies like Harvey (legal) and Abridge (healthcare) are building tighter, more defensible businesses with real revenue today. Infrastructure plays like Databricks and Cohere are somewhere in between. And the “wrapper” startups — companies that are essentially interfaces on top of OpenAI’s API — are the most precarious of all.
The distinction matters enormously for investors. A company with $200M ARR, real workflow lock-in, and a specific professional dataset is a fundamentally different bet from one with a $100B valuation and a promise of AGI.
“Vertical specialization wins. Harvey (legal), Sierra (customer service), Hippocratic (healthcare) dominate their niches because general-purpose tools can’t compete on depth.”
— AI Funding Tracker, Top AI Agent Startups 2026, aifundingtracker.com
Worth noting: Andreessen Horowitz’s April 2026 enterprise adoption report found that the industries successfully deploying AI share common characteristics — text-heavy work, repetitive tasks, natural human-in-the-loop involvement, and clearly verifiable outputs. Legal work, clinical documentation, software development. Industries that don’t fit these criteria (physical operations, relationship-dependent work, heavy regulation without verifiable end-states) are still early. That signal tells you a lot about which startups will still be growing in 2028.
The 4-Pillar Moat Framework Smart Investors Use
Before we get to specific companies, it’s worth spelling out the evaluation lens. Not every fast-growing AI startup is a good investment. The ones worth backing typically score well across four dimensions:
Proprietary Data
Does the company have access to domain-specific data that can’t be scraped or licensed by competitors? Harvey has legal case archives and firm-specific workflow data. Abridge has clinical conversation recordings with EHR integration.
Workflow Lock-In
Is the AI embedded deeply enough into daily operations that switching is painful? The best AI companies become load-bearing infrastructure. Look for EHR integrations, native document management hooks, and org-wide seat growth.
Revenue Velocity
ARR growth rate matters more than absolute ARR at this stage. Companies going from $50M to $200M ARR in 12 months have a fundamentally different growth engine than those plateauing at $80M.
Tier-1 Investor Backing
Sequoia, a16z, Kleiner Perkins, and Thrive Capital don’t just write checks — they run rigorous diligence. Their presence signals something real, even if it doesn’t guarantee returns. Multiple top-tier investors in the same company is a strong signal.
One more thing worth flagging: model dependency risk. Harvey actually scrapped its proprietary legal AI model in 2025 after frontier models from Google, xAI, OpenAI, and Anthropic began outperforming it on Harvey’s own BigLaw Bench evaluation. That sounds like a vulnerability — but Harvey’s response was to build model-agnostic agentic workflows that chain multiple LLMs together. Companies that understand they’re building on top of an evolving foundation, and structure their product accordingly, tend to last. Companies that think their proprietary model is the moat often don’t.
The 15 AI Startups Worth Serious Attention in 2026
These are listed roughly in order of investment clarity — starting with companies where the case is strongest and the revenue most verified, moving toward earlier-stage or riskier bets. All valuation and revenue figures are sourced from named publications and are as of May 2026 unless otherwise noted.
Harvey is, without much debate, the most successful vertical AI application to date by almost any metric. According to Sacra’s detailed analysis, it crossed $100M ARR in August 2025, roughly three years after founding, with weekly active users up 4x year-over-year. By year-end 2025, ARR had nearly doubled again to $190M, and a March 2026 growth round at $11B valuation was co-led by GIC and Sequoia.
What makes Harvey genuinely interesting — beyond the growth rate — is its evolution. The company started as a legal research tool and has progressively expanded into an agentic platform handling 400,000+ agentic queries per day, with 25,000+ custom workflows built by users. The strategic alliance with LexisNexis and deep Microsoft 365 Copilot integration (launching Q2 2026) mean Harvey is embedding itself into the actual software infrastructure lawyers use every day.
The land-and-expand model works almost comically well here: accounts typically start with a few hundred licenses, and internal data shows median seat count doubles within 12 months. The legal market is a $400 billion addressable opportunity in the US alone.
There’s no precedent for what Cursor has done. Bloomberg reported ARR exceeded $2 billion in early February 2026 — up from $100M just 13 months earlier. Going from $0 to $2B ARR in under 24 months isn’t just fast for software; it may be the fastest ever recorded for a B2B SaaS company, full stop.
Cursor’s product is an AI-native code editor built on VS Code. Its Tab completion predicts multi-line edits; its agent mode can plan and execute across files. The Salesforce case is illustrative: 20,000 engineers reportedly use it with over 90% daily adoption. Revenue mix has shifted from mostly individual subscriptions to roughly 60% enterprise contracts as of early 2026.
The risk here is real. GitHub Copilot still leads broader developer preference surveys (42% top choice vs. Cursor’s position in the top 3, per 2025 Jellyfish data). The AI developer tools market is intensely competitive. Cursor’s moat is product quality and enterprise momentum — both of which can erode if Microsoft accelerates Copilot investment.
Abridge occupies a deeply defensible position in one of the largest, most underserved markets in healthcare: clinical documentation. Physicians spend more time on documentation than direct patient care — and Abridge’s ambient AI converts doctor-patient conversations into structured clinical notes in real time.
Sacra estimates Abridge crossed $100M ARR in May 2025, with contracted ARR reaching $117M by Q1 2025 and major deployments underway at Kaiser Permanente (24,600 physicians across 40 hospitals), Mayo Clinic, UPMC (targeting 12,000 clinicians by 2026), and Yale New Haven. In April 2026, Abridge raised a $316M Series E extension, with a16z maintaining its lead position.
The KLAS #1 ranking for Ambient AI in Revenue Cycle Management — for two consecutive years — matters more than most outsiders realise. Hospital procurement teams treat KLAS rankings as a primary filter. That creates a near-moat: even well-funded competitors struggle to displace an incumbent who’s already embedded in Epic EHR workflows and trusted by 200+ health systems.
Glean’s pitch is simple and resonates immediately with anyone who’s worked at a company with more than 200 employees: you can never find anything. Email threads, Slack archives, Google Drive documents, Confluence pages, Salesforce records — knowledge is scattered across a dozen disconnected systems. Glean builds a unified AI search layer across all of them, letting users surface information and execute actions through a single interface.
The company doubled ARR from $100M to $200M in nine months — a growth rate that very few enterprise SaaS companies achieve. Its December 2025 Series F valued it at $7.2B with $410M total funding. Clients include Databricks, Confluent, Reddit, Sony Electronics, and Duolingo.
The a16z report cited Glean as the primary startup vendor for internal enterprise knowledge search — a category-defining position that’s hard to displace once an organisation has connected all its data sources to the platform.
Sierra reached $100M ARR in seven quarters — an extraordinary pace, though it’s worth noting Harvey and Cursor were faster. What distinguishes Sierra is its founder pedigree and pricing model. Bret Taylor (former Salesforce co-CEO) and Clay Bavor (former Google VP) are not first-time founders navigating enterprise sales blind. Taylor in particular has deep Salesforce relationships that shortened Sierra’s enterprise sales cycles materially.
The outcomes-based pricing — paying for completed work, not subscriptions — is a meaningful differentiator. It aligns incentives and makes ROI quantifiable, which matters when a company is deploying AI agents to handle patient authentication, process returns, or handle mortgage applications. Sierra’s Series C was $350M led by Greenoaks Capital, Sequoia, and Benchmark.
Cohere is one of the most intelligently positioned companies in the AI space, even if it doesn’t generate the same buzz as OpenAI or Anthropic. Its founder Aidan Gomez co-authored the Transformers paper — the foundational research that made modern LLMs possible. But Cohere didn’t chase ChatGPT. It pivoted toward “sovereign AI” — letting security-conscious enterprises deploy models within their own private cloud or on-premises infrastructure.
For regulated industries — banking, defence, government, insurance — this is genuinely important. GDPR compliance, data residency requirements, and liability concerns make “send all your data to an American hyperscaler” untenable for many large organisations. Cohere’s North agentic platform (launched for general availability August 2025) lets enterprises search internal data and automate tasks without their information leaving their perimeter.
Perplexity’s $520M-to-$20B valuation journey from early 2024 to late 2025 is one of the AI era’s most striking investor conviction stories — and also one of its more cautionary ones. The product is genuinely useful: cited, real-time answers that function as an alternative to Google for research-style queries. User growth has been strong.
The harder question is monetisation. Perplexity has faced persistent copyright disputes with media publishers and has been building toward an enterprise research product that would justify its valuation. The Motley Fool’s analysis noted that Perplexity is backed by SoftBank’s Vision Fund — both a stamp of credibility and, historically, a sign of capital deployment at expensive valuations.
Anthropic is the most directly investable foundation model company for accredited investors, primarily because it has shown up consistently on secondary market platforms and its cap table includes strategic investors (Google, Salesforce Ventures, Spark Capital) alongside large VCs. Its $13B Series F was the largest AI funding round of 2025.
The revenue trajectory is genuinely impressive: according to Inside AI Media, Anthropic reached $14B in annualized revenue at the time of its Series G (February 2026), growing more than 10x annually for three consecutive years. Claude Code in particular — Anthropic’s developer-focused coding CLI — has been one of 2026’s fastest-adopted enterprise developer products. The focus on AI safety isn’t just marketing; it’s becoming a procurement criterion for regulated industries.
If the AI startups above represent bets on specific application-layer winners, Databricks is a bet on the infrastructure that almost all of them depend on. The unified data lakehouse platform handles the messy, unglamorous work of actually storing, processing, and making data available to AI systems. Green Flag Digital’s ranking placed Databricks #2 overall in AI companies with $27.6B in total funding.
Databricks is one of the more anticipated IPO candidates of 2026-2027. A December 2025 Series L at $134B valuation makes it one of the most valuable private companies in the world. The Motley Fool described it as “one of the more anticipated IPOs for a while” — implying that public market access may eventually arrive. Secondary market shares are available on Forge Global and similar platforms, though at premium pricing.
ElevenLabs doubled its revenue in nine months to $200M and reached a $6.6B valuation, with customers building over 2 million AI voice agents that had already handled 33 million conversations by early 2026. The company’s voice synthesis technology is best-in-class by most independent benchmarks, and it’s moved intelligently from a simple voice cloning tool to a full voice agent platform with API infrastructure.
The voice modality is underappreciated. Phone-based customer service, accessibility tools, content localisation, IVR replacement — the use cases are enormous and relatively untapped. ElevenLabs is currently the default choice for developers building voice-first products.
Mistral occupies a unique structural position: it’s the leading European foundation model company at a time when European AI sovereignty is becoming a policy priority. Its models consistently rank highly on efficiency-to-performance benchmarks, and its open-weight releases (Mistral 7B, Mixtral) have established real developer credibility. NVIDIA and ASML — both critical AI infrastructure companies — are strategic investors.
The $13B valuation and €1.3B latest round is substantial for a two-year-old company. The bet here is partly geopolitical: the EU AI Act, GDPR, and data sovereignty concerns create real demand for a European AI provider that enterprises can deploy without legal risk.
Fast Company reported that 40% of U.S. doctors now log in to OpenEvidence daily — a user engagement figure that any consumer app would envy, achieved in a notoriously hard-to-penetrate professional market. The platform deploys teams of specialised PhD-level AI agents to answer complex clinical questions, drawing on peer-reviewed literature and delivering structured, actionable answers with citations.
The January 2026 round, led by Thrive Capital and DST Global at a $12B valuation (up from $3.5B just six months earlier), reflects extraordinary investor conviction. The caveat: a $12B valuation with limited public revenue data requires substantial ongoing growth to justify.
Devin was the first public demonstration of a fully autonomous AI software engineer — one that could plan tasks, write code across multiple files, run tests, fix its own bugs, and deploy applications without human direction at each step. The company raised $175M Series B with Founders Fund lead and Patrick and John Collison as angels. Peter Thiel’s involvement is notable — his track record on early bets (Facebook, Palantir, SpaceX) doesn’t guarantee returns but signals genuine conviction.
This is genuinely early-stage relative to Harvey or Cursor. The $2B valuation is a bet on a future where AI engineers handle significant portions of software development — possible, but far from certain, and the timeline is unclear.
Cerebras tripled in valuation from $8.1B to $23B in under six months — going from a September 2025 funding round to a new $1 billion round at $23B in early 2026. The company builds wafer-scale AI inference chips that are dramatically faster for certain AI workloads than NVIDIA GPUs. Its customer list — IBM, Meta, Perplexity, Mayo Clinic, Notion, AbbVie, GlaxoSmithKline — spans both enterprise software and life sciences, suggesting genuine product-market fit across multiple verticals.
The investment case here is that NVIDIA’s dominance of AI compute creates a structural incentive for large companies to diversify their AI chip supply. Cerebras is one of the most credible alternatives — alongside AMD and a handful of startups — with real data center deployments and revenue-generating clients.
Helsing achieved a €13.2B valuation after its €600M Series D, making it Europe’s most valuable AI defence company. The company builds AI software for defence applications — signal processing, sensor fusion, intelligence analysis. With European defence spending increasing sharply in response to the geopolitical environment since 2022, and governments actively seeking European AI alternatives to US platforms, Helsing is operating in a structural tailwind environment.
This is listed last because the risk profile is genuinely different. Defence AI investing requires accepting ethical considerations that many investors legitimately decline. Revenue is opaque, contracts are classified, and liquidity events are constrained. For investors comfortable with this asset class, however, the structural case is strong.
Full Comparison: 15 AI Startups at a Glance
| Company | Valuation | Latest ARR | ARR Multiple | Stage | Risk | IPO Likely? |
|---|---|---|---|---|---|---|
| Harvey AI | $11B | $190M | ~58x | Series F | Medium | 2026–27 |
| Cursor (Anysphere) | $29.3B | $2B+ | ~14.6x | Series D | Med-High | Unlikely Near-Term |
| Abridge | $5.3B | $100M+ | ~53x | Series E Ext. | Med-Low | 2027+ |
| Glean | $7.2–10B | $200M | ~36–50x | Series F | Medium | 2027 |
| Sierra | $10B+ | $100M+ | ~100x | Series C | Medium | 2027+ |
| Cohere | $7B | $100M+ | ~70x | Series E | Medium | 2027+ |
| Perplexity | $20B | Undisclosed | N/A | Growth | High | Possible 2026 |
| Anthropic | $183B | $14B | ~13x | Series G | Medium | Likely 2026–27 |
| Databricks | $134B | Undisclosed | N/A | Series L | Lower | Yes, 2026–27 |
| ElevenLabs | $6.6B | $200M | ~33x | Series C | Medium | 2027+ |
| Mistral AI | $13B | Undisclosed | N/A | Series C | High | 2027+ |
| OpenEvidence | $12B | Undisclosed | N/A | Series C | High | 2027+ |
| Cognition (Devin) | $2B | Early Stage | N/A | Series B | High | 2028+ |
| Cerebras | $23B | Undisclosed | N/A | Late-Stage | Medium | Possible 2026 |
| Helsing | €13.2B | Classified | N/A | Series D | Sector Risk | Unknown |
Note: ARR multiples based on disclosed figures. Where ARR is undisclosed, multiples are omitted rather than estimated. “Lower” risk reflects relative stability within an inherently high-risk asset class; no AI startup investment is low risk.
How to Actually Get In: The Techniques Experts Bury in Footnotes
Here’s where most investment guides get unhelpfully vague. They list impressive companies, then say “consider speaking to your financial advisor.” Let’s be more specific.
1. Secondary Marketplaces (Accredited Investors Only)
EquityZen and Forge Global are the two most established platforms. They aggregate shares from employees and early investors who need liquidity. Hiive is a newer entrant with bid/ask transparency. Linqto buys shares on its own balance sheet and sells blocks to investors, often with lower minimums. Expect minimum investments of $10,000–$25,000, limited availability for the most sought-after names, and months-long waitlists for companies like OpenAI or Anthropic. These require accredited investor status — $200,000 annual income or $1M net worth excluding primary residence.
Secondary market prices often exceed the last funding round valuation. You may be paying a premium to buy at a price the company itself hasn’t endorsed. Additionally, you’re paying fees and carry on top of that premium. Ensure you understand total cost basis before committing.
2. Publicly Traded AI-Focused Funds (Retail-Accessible)
For investors who don’t meet accredited investor thresholds, several publicly traded vehicles offer exposure to a basket of private AI companies:
- Fundrise Innovation Fund (VCX) — Holds stakes in Anthropic, Databricks, OpenAI, Anduril, and Canva. Available to retail investors. Quarterly redemptions.
- Destiny Tech100 (DXYZ) — Publicly traded fund owning shares in 36 private companies including Anthropic, SpaceX, and OpenAI. Note: often trades at a significant premium to NAV.
- ARK Venture Fund — Cathie Wood’s private company vehicle; invests in growth-stage private companies including AI names. Note: ARK’s public track record since 2021 warrants scrutiny before committing.
- Publicly traded companies with significant AI stakes — Microsoft (OpenAI, ~27%), Salesforce (Databricks, Google (Anthropic), Nvidia (various). These give diluted, indirect exposure but offer liquidity and transparency.
3. AI-Focused VC Funds (For Qualified Purchasers)
For investors above the $5M net worth “qualified purchaser” threshold, dedicated AI funds offer better terms and more direct access. Kleiner Perkins launched a $3.5 billion AI-dedicated fund in 2025 — the largest single-firm AI vehicle ever raised. Air Street Capital’s Fund III (London-based, closed March 2026 at $232M) invests in AI-first companies across frontier AI, autonomy, and TechBio. Radical Ventures closed Fund III at US$650M in October 2025, focused exclusively on AI. Access typically requires institutional introduction or placement agent relationships.
4. The Solo 401k Route (Often Overlooked)
Self-employed individuals and business owners with sole proprietorships can use a self-directed Solo 401k to invest in pre-IPO companies using pre-tax dollars. Providers like Rocket Dollar and Millennium Trust offer custodial services. The 2025 contribution limit was $77,500 (for those 50+). This doesn’t solve the accredited investor requirement, but it solves the tax efficiency problem for qualified investors who haven’t fully explored this route.
Portfolio Sizing Reality Check
Most institutional advisers recommend no more than 10–20% of a speculative portfolio in pre-IPO private equity — and that’s after you’ve covered emergency funds, public market diversification, and liquid alternatives. If you’re allocating to private AI startups, treat each position as potentially going to zero. The expected value can be compelling; the variance is extreme.
Red Flags: What to Avoid in AI Startup Investing
The euphoria around AI investing in 2025–2026 has created real opportunities — but also conditions that historically precede significant capital destruction. Here’s what to watch for:
- No Proprietary Data. Any AI startup that is purely a UI wrapper on top of GPT-4 or Claude’s API has essentially no moat. The model provider can build the same product themselves, and often will.
- Revenue Multiple Over 100x Without Exceptional Growth. Sierra at ~100x ARR is defensible given its growth rate and founders. A company at 100x ARR growing 20% year-over-year is not. Run the math on what growth is required to justify the valuation over a 5-year horizon.
- Demo Capability Gap. The distance between what AI agents can do in a curated 8-minute demo and what they reliably do in production environments is still significant for most tasks. Scrutinise customer case studies, not press releases.
- Single-Customer Concentration. For earlier-stage companies, check whether 50%+ of ARR comes from two or three logos. If it does, “ARR growth” is more vulnerable than it looks.
- Platforms Selling Secondary Shares at Premium to Last Round. The implied valuation on some secondary platforms exceeds the company’s last official funding round valuation. You could be buying at a price that makes positive returns arithmetically difficult.
- Conflating “AI Company” with Durable Business. A company that uses AI in marketing but earns revenue from something else isn’t an AI business. The valuation premium should only apply to genuine AI-native revenue.
Honest Verdict: What’s Worth Watching in 2026
The companies in this list aren’t equally interesting. A few are extraordinary businesses by almost any measure — Harvey’s ARR trajectory, Cursor’s B2B revenue growth, Abridge’s clinical workflow penetration, Glean’s enterprise search dominance. These are the cases where the numbers are real, the lock-in is structural, and the revenue multiples, while rich, are at least justifiable given the growth rates.
A second tier — Anthropic, Databricks, Cerebras — are less early-stage bets and more considerations about where and at what price to buy a known-quality asset. The IPO pipeline for these companies (Databricks and Anthropic are frequently mentioned for 2026–2027) may ultimately be a better access point than today’s secondary market premiums.
The third tier — Perplexity, Mistral, OpenEvidence, Cognition, Helsing — carries more uncertainty around either revenue verifiability, competitive durability, or sector-specific risk. That doesn’t make them bad investments; it makes them appropriate only for investors who can genuinely tolerate a wide range of outcomes.
The honest meta-point: the best AI investment opportunities of 2026 are largely inaccessible to most people at reasonable prices. The secondary markets price in optimism. The public proxies (Microsoft, NVIDIA, Salesforce) already have the AI bets priced in. That doesn’t mean there’s nothing to do — it means the work is finding the less-obvious angles: smaller AI funds with access to pre-hype rounds, secondary purchases after market corrections, or public-market infrastructure plays that are less directly correlated to specific model outcomes.
The AI era is genuinely different. The revenue numbers above — $2B ARR in 24 months, $100M in 36, 10x annual growth for three years running — are not marketing. They’re audited or closely-estimated real figures from credible sources. The underlying technology shift is real, the commercial adoption is real, and the investment opportunity is real. What requires realism is understanding exactly how that opportunity maps to an individual investor’s access, risk tolerance, and time horizon.
All figures reflect publicly reported data as of May 2026. Sources include Sacra, Crunchbase, PitchBook, TechCrunch, Bloomberg, Fast Company, Andreessen Horowitz research, and company disclosures. This article will be updated as material changes occur. It does not constitute investment advice.
More From AIEarnerHub
Essential reading for serious AI investors and builders
The Fastest-Growing AI Companies: Revenue, Valuations & What’s Really Driving the Boom
AI Tools That Might Change the Internet More Than ChatGPT
Trending AI Startups in the World 2026 🚀
AI INFRASTRUCTURE: INVESTMENT THESIS 2.0
Top 10 Trending AI Startups in the USA for 2026
The Top AI Companies in India: Advice That Sounds Right—But Is Quietly Holding You Back
Scalable Startups in 2026: How Founders Are Using AI
7 Copy AI Moves That Separate Beginners From Experts
AI Business Success Stories: What Actually Worked (And What the Numbers Are Hiding)
15 Profitable AI Startup Ideas You Can Start Today
AI Business Success Stories 2026
FAQ